Member Info for RichKen

This is from the recent cash raise and this will accelerate Avacta’s potential:
- £10 million is ready for a rapid scale-up of Diagnostics Business,
- Working capital for the COVID-19 testing opportunity
- Expansion of in-house diagnostics product development capabilities including
facilities, capital equipment; scientific, commercial and senior leadership teams
- Acceleration of broader diagnostics product pipeline and commercial partnerships
-£38 million is ready to accelerate the Expansion of Pipeline of Differentiated Cancer Therapies:
- Rapidly growing the pre|CISION™ pre-clinical pipeline and delivering pre-clinical packages for several pro-drugs (pre|CISION™ velcade, paclitaxel and oxaliplatin).
- Expanding the Affimer® immunotherapy pipeline (PDL1-TGFß inhibitor and PDL1-cytokine bispecifics).
- IND/CTA filings for one or more Affimer immunotherapies (TMAC drug conjugate (PDL1-IDASH) or first bispecific candidate) and one or more pre|CISION pro-drugs.
- Obtain first-in-human data for the Affimer® platform.
- UK phase I clinical trial for first pre|CISION™ chemotherapy AVA6000 pro-doxorubicin covered by current cash reserves, with the proceeds of the Fundraise being used to fund IND filing AVA6000.
- Total Number of Shares is now 235,152,097
- Avacta has a new significant STRATEGIC US investor added to its shareholder base
- Employees are getting shares which will reward there hardwork

Alastair Smith and the Board "anticipates strong near-term news flow relating to the COVID-19 test developments with Cytiva and Adeptrix, as well as commercial and technical progress in the established therapeutic and diagnostics businesses, allowing the Company to concurrently achieve multiple value inflection points that we expect will deliver substantial shareholder returns. I look forward to updating the market on our continued progress."

I expect a very strong news flow and a new partnership which will really open up a very strong future for Avacta - Think pre|CISION™ Therapeutics!! Attaching drugs to Affimers and you have a precision drug warhead with reduced or no side effects! This is where the real value will come!

Cheers Rich

The targets for future Affimer pre|CISION

Avacta has so much potential in this particular area.

The first is AVA6000 Pro-doxorubicin, Doxorubicin has been a standard of care treatment for advanced soft tissue sarcoma (ASTS) for 40 years. Treatment is currently limited to six cycles due to cumulative cardio-toxicity. However, the global market for this generic drug is still $1bn. AVA6000 Market Opportunity for three opportunities ASTS, breast and ovarian cancer, with peak sales for a safer and more efficacious form of dox in the US/EU alone is estimated to be $1.5bn pa with a 5-10% royalty to Avacta plus development milestones in the near term. This is an incredible prospect!

But then the opportunities to use the recent funds to develop the additional pipeline of pre|CISION pro-drugs, some of which have already been synthesized, with an addressable market of many $billions per year.
Including these drugs but not limited to:
• preCISION Velcade
• preCISION Paclitaxel
• preCISION Oxaliplatin
• preCISION Gemcitabine
• preCISION Capecitabine
• preCISION PARP inhibitor
• preCISION PD-1 Inhibitor
• preCISION AKT inhibitor
• preCISION Balixafortide

The combination of Avacta’s two proprietary platforms to deliver chemotherapy and immunotherapy in a single drug molecule has two key points:

The "warhead"
Released in the tumour by the preCISION linker chemistry.
• Selected to kill tumour cells and create an inflammatory event that recruits the immune system.
• Potential for a pipeline of TMACs using different immuno-active warheads

Then the Affimer Immunotherapy:
• Supports the immune attack on the tumour by blocking the signal the tumour uses to evade the immune system.
• Potential of a pipeline of immunotherapy and targeting Affimers including bispecifics

If the trials are successful with AVA6000 the developments in these other treatments will surely be accelerated. Within 2 to 3 years we could see the results of these developments being used in Oncology clinics around world saving lives.

This area has massive potential!

Cheers Rich

This presentation will help understand the pre|CISION chemotherapy treatment in the first trial coming later this year.
https://avacta.com/alastair-smith-provides-overview-of-precision-prodrug-technology-and-update-on-ava6000-clinical-trial/
I hope this helps many trying to see where this is going.
Cheers Rich

When we look at the potential for Avacta it is all about Affimer technology.

This is a patented technology which is used to detect proteins and works like a magnet. The Affimer is a powerful magnet and the target is like particles of iron fillings and those targets are found quickly in the body.

We have seen that Avacta have developed the pre|CISION technology for delivering a drug to a target, with the focus on chemotherapy drugs to cancer cells.

Then our focus is currently on diagnostics and right now having a group of Affimers which can detect the protein on the spike on the Covid19 virus. This will come to market either in the form of lab diagnostic or on a test which will use a simple strip like a pregnancy test called a lateral flow device. This Avacta test will use saliva.

The potential is to be able to use Affirmers for diagnostics in many other deceases and illnesses. But given the work in cancer treatments which will go through stage 1 trials late this year and completed in Q1 2021, it is more than possible that Affirmers could be used for diagnostics in oncology. This would speed up the opportunity to treat a patient. The company have not given anything of this away at this point, but it must be a strong possibility. Imagine you have a simple diagnostic test to specific cancers and then you could use a targeted treatment to destroy the cancer cells, the whole oncology process could be simplified and this would save billions financially and of course save lives. The combination for Avacta IP could prove to be incredible.

It is a question I think I would like to see answered by Alastair Smith at some point in the future.

Does anyone else think this is possible? The impact would be huge.

Cheers Rich.

Monkshood, many thanks for your information. I was asking a lab technician in our local hospital about BAMS and that was the information I was given.

It sounds to me that your level of expertise on this is far greater than I was able to glean from a short three to four-minute conversation!

The information shared, is very helpful. Thank you very much for sharing. As well as the other links below. It gives us all a much greater understanding.

Cheers, Rich

From this weeks information from Avacta, this is surely one of the most interesting and informative presentations yet?
https://avacta.com/how-diagnostic-test-performance-is-measured/

Cheers, Rich

I think he most likely is invested from that time! This investment was discussed in many BMN groups and he may be in one of those.
My first buy was at 38p also. £50k.
Great investment and now hold a very strong investment here.
Cheers Rich

Zoom, I am not surprised at all to see so many Bushveld Minerals investors building a holding here. There are some very high net worth individuals who I know well on that board and building a holding here quietly is highly likely. They all like companies with great fundamentals and huge upside.
Avacta is a perfect Investment for these investors. Well managed, excellent communication and very clear long term upside. The key to a good investment is to have the right ingredients. Bushveld went from 5p to 50p. It currently sits at the bottom of a cycle but it remains one of the highest earning AIM listed miners and mineral processors. With significant profit.
I only point this out, because if Avacta complete the trio with Covid19 and progress with the pre|CISION cancer treatments they will have profits and growth like no other AIM investment. Exceeding Boohoo and other high value AIM companies market caps.
The other common point is duel listing and move to the FTSE is likely with both businesses in the future.
I feel currently that Avacta has the ability to our pace BMN over the next 12 months, but both will be very successful companies.
Anyway here and now my focus and all here are interested in Avacta.
Nice to see people building there holdings here.
Cheers Rich

This came up in an earlier post - what else could Avacta do with LFD using Affimers?

If they can match the proteins for diseases, cancers, viruses, then surely there is no limit to its uses. Imagine instead of a CT scan you could use an LFD for looking for the specific cancer cell and mean the correct pre|CISION product with the attached drug could be focused to destroy that tumour. This could take away weeks of waiting and take us to the right specialist and save health services around the world billions. This diagnostic market has massive potential! This is just the second use that Avacta has got to the point where it is close to market readiness!
Cheers, Rich

David1951c,
My friend Ophidian posted a timeline of the processes here, based on years of experience in this industry. I am sure he will not mind me posting it for you!

"1. R&D work to establish a proof of concept - DONE
2. Development work to establish the design to take forward - DONE
3. Collaboration with third party device manufacturer to define product - DONE

4. Third party device manufacturer established final design to take forward - DONE
5. First batches to final design made at pilot scale (and put on stability to generate supporting data) - DONE
6. Examples from pilot scale devices supplied to Avacta for further evaluation and lab testing - DONE
(these are probably what he calls Prototypes)
7. Additional batches made again at pilot scale to clinical standards for first time clinical evaluation. Supplied Wk3/Wk4 June Time to complete 21-28 Days
8. In parallel with clinical programme; Scale up to production scale. Include Tech transfer and validation batches (again put on stability to generate data)
9. Evaluate data from clinical programme (establishes the Selectivity and Sensitivity of the test) July Wk.2s/wk3
10. Generate the Regulatory dossier including clinical data, stability data, development data and supporting data from early designs Wk2/wk3/wk4 July
11. Submit Regulatory dossier and if not already ongoing be manufacturing launch stocks 1st August
12. Get approval Wk3 August
13. Start selling Wk3/4 August

I am very happy with today's RNS (24th June) first lab batches tested and the LFD design now completely de-risked. There will be some minor tweaking now from the lab data to produce the batches that will be used for clinical validation and whilst they SHOULD freeze the process in this time of rapid development they won't and there will be further optimisations in the Xfer to production and tech transfers to manufacturing partners. This will be covered by ongoing commitments post-registration so won't hold anything up. Avacta have played an absolute blinder here I can't start to say how impressive their progress is to date. Now totally de-risked both LFD and BAMS will pretty soon dominate the market place in my view. Next RNS I want is manufacturing partners (and volumes potentially). I'm also interested in hearing what the selling price might be so we can start to rattle the piggy bank.

I made a minor amendment to the Timeline to mark lab tests as DONE - nothing else needs changing. All on course.

Ophidian"

I hope this helps,

Cheers, Rich

Yes, I am pointing people to another great write up on the Avacta News stream.
They would not be making so much of this if we were not about to release to the market on of the best ‘Point of Care’ diagnostic tools for testing yet seen. https://avacta.com/responding-to-disease-outbreaks-the-importance-of-point-of-care-diagnostics/
A worthy read.
Cheers Rich

Good evening all,
I think from what I have been asking there are a huge number of mass spectrometers around the UK NHS and around the world, they are one of the key pieces of equipment in labs in hospitals. The key for Avacta is having the correct partners which are able to supply the trialled Affimers and distribute them for their machines. They certainly have the ability in the lab to actually become a very accurate test indeed and without the variances which have been found in PCR depending on the quality of the swabs. The attaraction to the specific protein from the Affimer being like iron fillings to a magnet means the results are going to be highly specific.
We are still looking forward to an update on these partnerships and we should be there very quickly.
The two tests are going to cover a huge global need for testing and the key will be consistency, simplicity and possibly the most important a cost advantage to health service business around the planet.
Given the current pathway by many governments including our own and peoples lack of a sensible response the requirements for testing are just going to multiply over and over both in lab and at point of care.
It will be such good news in every way for the populous and Avacta investors as soon as theses tests can become globally available.
Cheers Rich

The news items due in the immediate future are partnerships.
- production partnerships for LFD
- distribution partnerships for BAMS
- Pharmeceutical partnership for virus neutraliser

There after the detailed information on the testing options with the final production items.

Then the orders....

The largest market is going to be the America’s, north and south, Asia and Europe. I wonder if the UK maybe Avacta’s smallest market? Certainly in the short term.

The news I am really looking forward to is the commencement of phase 1 trials of the pre|CISION AVA6000 chemotherapy Affimer technology therapeutic.

I am very happy to wait and digest the news as it comes.

Have a good day all!

Cheers Rich.

Likely to cover a short!
The SP jumped to 154 this morning in the RNS spike. Then dropped to £1.30. In just 90 minutes. How is that possible given the news.
That is thanks to shorting the stock. Look at the posts this morning.
It is clear.
Cheers Rich

It amazes me that when you have a full explanation of who the business can be valued - many thanks to Myles for being able to share this fully via his own website - it is clear how this business value calculated by some become clear. This is not ramping it is working out business value. I have shared pointers to this myself many times. Which has pointed to numbers similar to those given by Myles? Clearly we make slightly different assumptions but the numbers give an idea to investor value being created.
Yet there are a multitude of posters on this board who patrol it from morning till night, trying to downplay the real value here.
I would say the value is clear to see. Just because this is an AIM-listed business it does not mean it cannot succeed. It will.
I do hope that the many genuine investors who read this board can see through the rubbish posted here. Though it is not easy for the none business minded which is a great shame.
For those willing to invest and build up a holding here the future looks very good indeed. I would recommend you read the company website and the comments by Myles and try to ignore the less helpful comments posted here from morning till night by a small group trying to play this business down. They will not affect it. The company is driven by its IP and the market.
Cheers, Rich

The Introduction:
Avacta is a Biotech company with two operating segments, the Therapeutics operations based at Avacta’s Cambridge site (pre|CISION™ ) and the Diagnostics operations ( Affimer® ) in Wetherby.

The Expertise!
Avacta has two key areas - Affimer® technology a uniquely developed technology which is used as a diagnostic to find virus’s based on a human protein called Stefin A. The Affimer® platform is Avacta’s proprietary therapeutic platform with its intellectual property covered by several patent families.

Projects:
Affimer® technology projects with LG Chem just on licensing can be worth up to $310 million.
ADC project backed by Astra Zeneca for PBD Warheads - loaded affirmer drugs $500 million.
A joint venture in South Korea with Daewoong a leading Korean pharma company, to develop the next generation of cell and gene therapies, incorporating Affimer proteins to enhance the immune-modulatory effects. Avacta holds 45% of the business but the finance is provided by venture capitalists where the market potential is still too large to actually pinpoint as there are NDA's in place so the market information can't be shared. Huge potential!
The huge project with Affimer® technology with Moderna which again will give drug deliveries for mRNA delivery is still progressing. Huge potential!

Affimer® technology to detect Covid19 using Antigen tests the partners are Cytiva (LFD) and Adeptrix (BOMS) with distribution through 4 Mass Spectrometer suppliers (both close to production)
There are existing 5 other Affirmer evaluations progressing, 17 other projects already delivered for evaluation, and a further 7 development projects initiated!

The Expertise:
Avacta’s pre|CISION™ technology can be utilised in a drug conjugate linker or to generate chemotherapy pro-drugs that are only activated in the tumour.
When added to a chemotoxin, the pre|CISION™ substrate prevents the chemotoxin from entering cells and therefore renders it inert until the substrate is cleaved in the tumour microenvironment. Using this pro-drug approach, the systemic exposure to the chemotoxin is dramatically reduced, and the safety and therapeutic window of these powerful anti-cancer treatments are improved.

The projects:
pre|CISION™ partnerships which are looking to start with opportunities in AST, Breast and Ovarian cancer the EU/ US market potential is around $1.5 billion.

Research Opportunities for the reader:

Broker Note: https://mcusercontent.com/d9ebd7c1aa0f3dbc5fab42eca/files/28b0a706-057a-4dda-bc5f-e24c2afca3cd/AvactaGroupplc_24_6_20_FINAL_BG.01.pdf

The last Presentation:
https://youtu.be/DzoxXCB4or0 - from 1hr 33min 50 seconds

Latest from Avacta: https://avacta.com/how-diagnostic-test-performance-is-measured/

A good read from a well-known researcher is found here:
https://aimchaos.files.wordpress.com/2020/06/avacta-group-update-ii-part-iii-1.pdf

Investment decision for 2020? Surely it looks good!
Cheers Rich

Good morning all,

It is amazing the company delivers the next stage of its progress and we get a vist from a 'silent watcher' today. How convenient. Shame you did join us all in February when you could have got in for 20p.
The company has in the last 3 months made huge progress. It clearly has Affitmer technology which does work, that has been proven by progress at Adeptrix and now Cytiva and now the LFA is being optimised by Cytiva ready for production at the soon to be announced UK production partners. The first of potentially a number of partners around the world.
Make no mistake that this is going to production and the accuracy of the positive and negativity as outlined yesterday is going to be at such a level that this will be a global bestseller.
In 6 months this company will have been transformed from a research biotech partner and developer to a full diagnostic supply production business having been given a massive opportunity.
The potential is hundreds of millions of sales with a profit margin for all partners and a margin for Avacta in excess of 70p per unit.

So 'Truth and Trust' - I don't think you are fooling anyone here with 'Deceit and Lies'. I think most people can see you have an alternative agenda who are well researched.

I am very happy to listen to what we are being told by the experts thanks very much. This company is one a pathway that you will not be able to stop. people need to listen to the CEO and consider the work that his team have brought this company too. The IP of Avacta is hugely valuable and in 2020 its value is going to be worth very much more and investors will see the impact of this.
Cheers, Rich

This surely is one of the most significant days in Avacta’s progress as a company. The news the test works as outlined it would. But working with Cytiva for bringing the product together.
Now the completion of the design and likely announcements of a minimum of two production partnerships in the UK and then very likely overseas partners too.
One huge step.
Excellent!
Good day going to be here!
Cheers Rich

I do wonder if the BAMS test using our precise Affimer technology will be more sensitive and have an ability to be more specific even with less precise swabs. Surely we only need a saliva swabs. If they can use this effectively it will be the gold standard lab test.
Accuracy and simplicity as well as lower costs will be critical going forward. On BAMS compared to PCR we will be the newcomer, a bit like Blueray replacing DVD. Higher definition and clarity. That is key to virus checking.
Just my thoughts.
Cheers Rich

A must watch for all Avacta investors.

https://avacta.com/how-diagnostic-test-performance-is-measured/

Today I bought another £20k’s worth of shares. They dropped the price I bought more. Thanks MM’s.
The portfolio is growing nicely.
Cheers Rich